210 related articles for article (PubMed ID: 11561871)
1. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
Sakalová A; Bock PR; Dedík L; Hanisch J; Schiess W; Gazová S; Chabronová I; Holomanova D; Mistrík M; Hrubisko M
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S38-44. PubMed ID: 11561871
[TBL] [Abstract][Full Text] [Related]
2. Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients--results of an epidemiological multicentre retrolective cohort study.
Beuth J; Ost B; Pakdaman A; Rethfeldt E; Bock PR; Hanisch J; Schneider B
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S45-54. PubMed ID: 11561873
[TBL] [Abstract][Full Text] [Related]
3. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Bladé J; San Miguel JF; Alcalá A; Maldonado J; Sanz MA; García-Conde J; Moro MJ; Alonso C; Besalduch J; Zubizarreta A
J Clin Oncol; 1993 Jun; 11(6):1165-71. PubMed ID: 8501503
[TBL] [Abstract][Full Text] [Related]
4. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Apajalahti J; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Järvenpää E
Eur J Haematol; 1987 Jan; 38(1):50-4. PubMed ID: 3582605
[TBL] [Abstract][Full Text] [Related]
5. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
6. Influence of a complementary treatment with oral enzymes on patients with colorectal cancers--an epidemiological retrolective cohort study.
Popiela T; Kulig J; Hanisch J; Bock PR
Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S55-63. PubMed ID: 11561874
[TBL] [Abstract][Full Text] [Related]
7. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Gyllenhammar H; Johansson B; Juliusson G; Järnmark M
Eur J Haematol; 1989 Jul; 43(1):54-62. PubMed ID: 2670605
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
9. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
[TBL] [Abstract][Full Text] [Related]
10. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multiple myeloma in old patients. Finnish Leukaemia Group.
Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Hänninen A; Ilvonen M; Isomaa B; Jouppila J; Järvenpää E; Kilpi H
Eur J Haematol; 1989 Oct; 43(4):328-31. PubMed ID: 2583258
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group.
Palva IP; Ala-Harja K; Almqvist A; Elonen E; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Jouppila J; Järvenpää E
Eur J Haematol; 1993 Aug; 51(2):98-101. PubMed ID: 8370425
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
[TBL] [Abstract][Full Text] [Related]
14. Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
Takenaka T; Itoh K; Suzuki T; Utsunomiya A; Matsuda S; Chou T; Sai T; Sano M; Konda S; Ohno T; Mikuni C; Deura K; Yamada T; Mizorogi F; Nagoshi H; Tomonaga M; Hotta T; Kawano K; Tsushita K; Hirano M; Shimoyama M;
Int J Hematol; 2004 Feb; 79(2):165-73. PubMed ID: 15005346
[TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple myeloma in elderly people: long-term results in 178 patients.
Bladé J; Muñoz M; Fontanillas M; San Miguel J; Alcalá A; Maldonado J; Besses C; Moro MJ; García-Conde J; Rozman C; Montserrat E; Estapé J
Age Ageing; 1996 Sep; 25(5):357-61. PubMed ID: 8921139
[TBL] [Abstract][Full Text] [Related]
16. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
[TBL] [Abstract][Full Text] [Related]
19. Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
Chou T; Tobinai K; Uike N; Asakawa T; Saito I; Fukuda H; Mizoroki F; Ando K; Iida S; Ueda R; Tsukasaki K; Hotta T;
Jpn J Clin Oncol; 2011 Apr; 41(4):586-9. PubMed ID: 21247967
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
